BioNJ welcomes our new Innovation Members:

ARKAY Therapeutics, LLC
ARKAY Therapeutics is a preclinical stage biopharmaceutical dedicated to developing and commercializing personalized medicines for Type 2 Diabetes and Pre-Diabetes. The company’s mission is to improve the life style and life span of Type 2 Diabetes patients. We are targeting immunomodulation-inflammation-insulin resistance axis to fill a gap that currently exists in the modalities that are used for treating Type 2 Diabetes. ARKAY has established an intellectual space for the company to operate by filing U.S. and PCT patent applications titled “Formulations and methods for treatment of Metabolic Syndrome.” ARKAY has successfully completed a pilot POC study with its lead product combination and the long term definitive study is currently underway. We are on track to bring an innovative anti-inflammatory centric combination product to the market in 4 to 5 years.

BioIncept, LLC
Biolncept is a privately-held, clinical stage company committed to the development of innovative therapeutic and diagnostic products based on the groundbreaking discovery of Prelmplantation Factor (PI F). Eytan R. Barnea, MD, FACOG, Chief Scientific Officer and Co-Founder, discovered naturally occurring PIF in mammalian embryos and uncovered its broad implications in pregnancy, immunity and transplant. To translate the clinical study of PIF, the company developed synthetic PIF (sPIF), including human grade sPIF intended for use in human trials. With a top-tier management team, a global network of scientific collaborators and a robust intellectual property portfolio/patent estate, Biolncept is well positioned to achieve its mission of delivering on the promise of PIF for patients with significant unmet needs.

Biotranex LLC
Biotranex is a science-driven contract research laboratory. We are dedicated scientists with proven track records of success in drug discovery and development. We provide comprehensive solutions for ADME/PK, chemistry/lead optimization and biomarker/structural biology issues. We do problem solving for our clients to reduce the attrition rate of drug development. We deliver high quality services in a timely fashion.

Clinical Genomics
Clinical Genomics is a privately held Sydney-based biotechnology company developing next generation products for colorectal cancer diagnosis. Clinical Genomics currently holds a portfolio of more than 20 patents and patents pending. In 2013, Clinical Genomics acquired the US-based cancer screening company Enterix Inc. from Quest Diagnostics as well as the Sydney-based subsidiary. The acquisition provides Clinical Genomics with a regulatory-licensed manufacturing facility in the US and Australia and access to a specialty pathology laboratory in Australia for selling bowel cancer screening services. Clinical Genomics owns the patented InSure faecal immunochemical test (FIT) ‘Brush test’ product line. This product, combined with the new blood plasma test (ColoVantage Plasma), delivers a portfolio of colorectal cancer screening products aimed at user-friendly, patient-preferred screening solutions. Clinical Genomics now has facilities in Sydney, Australia and Edison, New Jersey in the US, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.

Cormedix Inc.
CorMedix is an emerging commercial-stage biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of infectious and inflammatory diseases. CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients, in addition to oncology patients, critical care patients and patients receiving total parenteral nutrition, IV hydration and/or IV medications. CorMedix initiated a Phase III clinical study in the US in December 2015. The initial and subsequent products under development will address significant unmet needs in the US and in the rest of the world.

Milestone Pharmaceuticals
Milestone Pharmaceuticals focuses on cardiovascular diseases. It utilizes de-risked mechanism of actions in developing novel treatments. Milestone is developing a breakthrough therapy for paroxysmal supra-ventricular tachycardia (PSVT), a serious electrical disorder of the heart. Milestone’s lead product, Etripamil, is a novel intranasal calcium channel blocker that will provide PSVT patients with a convenient, safe and rapidly effective therapy that they can take at the onset of an episode. The product is in Phase 2. Etripamil represents a significant commercial opportunity: extensive market research has validated the unmet need in PSVT filled by Etripamil and supports a rigorous sales forecast of> $600 M in the USA and> $1 B globally.

Motif Bio
Motif is a clinical-stage biopharmaceutical company, specializing in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018.

Nucana, Inc.
NuCana® is a rapidly growing, Phase III clinical stage biopharmaceutical company developing an expansive portfolio of new medicines to treat cancer. With its new generation of anti-cancer agents (nucleotide analogues), NuCana is setting advanced benchmarks for innovative treatments. NuCana is transforming anti-cancer agents (nucleoside analogues) into better and safer medicines that overcome key tumor resistance mechanisms. Our state-of-the-art ProTide technology ensures that significantly more active agent is being generated within the cancer cells. Acelarin (NUC-1031) is NuCana’s first ProTide to enter the clinic and has achieved exceptional levels of disease control in a comprehensive study of patients with advanced, rapidly progressing solid tumors.

Ovid Therapeutics
Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. We were founded to leverage recent advances in science and medicine to find optimal therapies. We seek to identify and develop late stage, de-risked medicines with significant potential. Our rationale for developing these medicines is based on key insights from our scientific founders and confirmed in discussions with leading experts in the field. We apply the most efficient processes to bring safe and effective therapies to patients. We have collaborators and are working with patients across the US and around the globe.

Patagonia Pharmaceuticals
Patagonia is a specialty pharmaceutical company developing innovative therapies for dermatological diseases such as ichthyosis. It is based out of New Jersey.

Radius Health, Inc.
Radius is a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The company’s lead investigational drug product candidate, Abaloparatide (BA058), is in development, in both injection and methods of administration, for the potential prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius’ clinical portfolio also includes a new investigational oral agent, RAD1901, a selective estrogen receptor down-regulator/degrader, or SERD, in development at higher doses for the potential treatment of breast cancer brain metastases, and at lower doses as a selective estrogen-receptor modulator, or SERM, for the potential treatment of vasomotor symptoms such as hot flashes.

Simphotek, Inc.
Simphotek is involved in research and development related to drug developments and their use in animal studies and/or human clinical trials with collaborators at the Hospital of the University of Pennsylvania. There is a close working relationship with our collaborators in the laboratories and the hospital to develop light-based drug therapy for various forms of cancer, including head and neck, lung, brain and other major forms of cancer. Simphotek helps design light-drug laboratory/clinical experiments and analyzes experimental animal and clinical research. Simphotek technology requires FDA approval.